Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

9 Although the 75 mg dose did show increased efficacy versus placebo at week 16 (41.1% vs 28.4% for ASAS 20), it did not reach statistical significance based on the hierarchical hypothesis testing that controlled for multiplicity of testing. 9 In the present analysis, clinical improvements were sustained through week 156 across all measured end points for secukinumab 150 mg, thus supporting the long-term suitability of secukinumab for controlling the signs and symptoms of AS.

also in 111,027 other papers